FGF2 overexpression promotes resistance to endocrine therapy in breast cancer by modulating hormone receptor expression and WNT signaling

LANARI, CLAUDIA; SAHORES, ANA; FIGUEROA, VIRGINIA; LAMB, CAROLINE

San Carlos de Bariloche

Congreso; SISTAM; 2018

SISTAM

Approximately two-thirds of breast cancers express hormone receptors and thus, endocrine therapy is the standard treatment. However, some patients are refractory or develop resistance after therapy, by mechanisms that may include deregulation of growth factor signaling pathways. Fibroblast growth factor 2 (FGF2) consists of a secreted low molecular weight form (LMW-FGF2) and several nuclear high molecular weight forms (HMW-FGF2). We previously demonstrated that FGF2-overexpression induced resistance in endocrine responsive T47D-YA and T47D cell lines (1). Additionally, our group has demonstrated that antiprogestin resistant tumors display low progesterone receptor isoform A (PRA)/isoform B (PRB) ratio (2), which is consistent with our current evidence.